Latest on Lupus Clinical Trials

Clinical trials help to answer the question, “Will this drug help people and be safe to take?”

At any given time, there are thousands of clinical trials going on. And finally, there are increasing numbers of lupus clinical trials.

Clinical trials are critical in the search for a better life for people with lupus.

Could You Be Part of the Solution?

Find out on our special website, LupusTrials.org.

LupusTrials.org

What Are They Showing?

See the latest in results of clinical trials as they are reported in medical journals on the U.S. National Library of Medicine’s vast database of biomedical articles (PubMed). Some interesting ones from recent months include:

Anthera Updates Phase 3 Plans Following Results from the Phase 2b PEARL-SC Dose Ranging Study of Blisibimod

New Study Shows Potential Benefit of Existing Organ Transplant Medication for Lupus Nephritis

Evaluation of Lenalidomide (REVLIMID®) to Treat Subjects With Cutaneous Lupus Erythematosus (CLE)
Arthritis Research & Therapy 2012, 14:R265 doi:10.1186/ar4111

Blisibimod, an Inhibitor of B cell Activating Factor, in Patients with Moderate-to-Severe Systemic Lupus Erythematosus
Poster Presentation at 2012 Annual Scientific Meeting of the American College of Rheumatology and the Association of Rheumatology Health Professionals (ACR/ARHP)

Belimumab reduces autoantibodies, normalizes low complement levels, and reduces select B cell populations in patients with systemic lupus erythematosus
Arthritis & Rheumatism Volume 64, Issue 7, pages 2328–2337, July 2012

Mycophenolate as Induction Therapy in Lupus Nephritis with Renal Function Impairment
American Journal of Nephrology Am J Nephrol 2012;35:424-433 (DOI: 10.1159/000337916

Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: The lupus nephritis assessment with rituximab (LUNAR) study.
Arthritis Rheum. 2012 Jan 9. doi: 10.1002/art.34359. [Epub ahead of print]

Use of atorvastatin in systemic lupus erythematosus in children and adolescents.

Arthritis Rheum. 2012 Jan;64(1):285-96. doi: 10.1002/art.30645.

Pioglitazone improves the cardiovascular profile in patients with uncomplicated systemic lupus erythematosus: a double-blind randomized clinical trial.
Lupus 2012;21(1):27-35. Epub 2011 Oct 12.

Patients with systemic lupus erythematosus, myositis, rheumatoid arthritis and scleroderma share activation of a common type I interferon pathway.
Ann Rheum Dis. 2011 Nov;70(11):2029-36. Epub 2011 Jul 28.

Patients with systemic lupus erythematosus, myositis, rheumatoid arthritis and scleroderma share activation of a common type I interferon pathway.
Ann Rheum Dis. 2011 Nov;70(11):2029-36. Epub 2011 Jul 28.

Safety profile and clinical activity of sifalimumab, a fully human anti-interferon a monoclonal antibody, in systemic lupus erythematosus: a phase I, multicentre, double-blind randomised study.

Ann Rheum Dis. 2011 Nov;70(11):1905-13. Epub 2011 Jul 27.

Memantine in systemic lupus erythematosus: a randomized, double-blind placebo-controlled trial.

Semin Arthritis Rheum. 2011 Oct;41(2):194-202. Epub 2011 Apr 1.

Pharmacokinetics, pharmacodynamics and safety of a human anti-IL-6 monoclonal antibody (sirukumab) in healthy subjects in a first-in-human study.
Br J Clin Pharmacol. 2011 Aug;72(2):270-81. doi: 10.1111/j.1365-2125.2011.03964.x.

Scleroderma overlap syndrome
Isr Med Assoc J. 2011 Jan;13(1):14-20.

Efficacy and safety of tacrolimus therapy for lupus nephritis: a systematic review of clinical trials.
Lupus. 2011 Mar 7.

Treatment of active lupus nephritis with the novel immunosuppressant 15-deoxyspergualin: an open-label dose escalation study.
Arthritis Res Ther. 2011 Mar 1;13(2):R36.

Targeted therapies in systemic lupus erythematosus: successes, failures and future.
Hahn BH.
Ann Rheum Dis. 2011 Mar;70 Suppl 1:i64-i66. Review.

The genetics of systemic lupus erythematosus and implications for targeted therapy.
Ann Rheum Dis. 2011 Mar;70 Suppl 1:i37-43. Review.

Targeting BLyS in rheumatic disease: the sometimes-bumpy road from bench to bedside.
Curr Opin Rheumatol. 2011 May;23(3):305-10.

Systematic review and meta-analysis of immunosuppressant therapy clinical trials in membranous lupus nephritis.
J Investig Med. 2011 Feb;59(2):246-58.

Type I interferon in organ-targeted autoimmune and inflammatory diseases.
Arthritis Res Ther. 2010;12 Suppl 1:S5. Epub 2010 Aug 25.

Antiphospholipid Syndrome Clinical Research Task Force report.
Lupus. 2011 Feb;20(2):219-24.

Report of the Obstetric APS Task Force: 13th International Congress on Antiphospholipid Antibodies, 13th April 2010.
Lupus. 2011 Feb;20(2):158-64.

Novel treatments for systemic lupus erythematosus.
Curr Opin Investig Drugs. 2010 Nov;11(11):1256-64.

International consensus for a definition of disease flare in lupus.
Lupus. 2010 Dec 10.

B cell depletion for autoimmune diseases in paediatric patients.
Clin Rheumatol. 2011 Jan;30(1):87-97.

Primary thrombosis prophylaxis in antiphospholipid antibody-positive patients: where do we stand?
Curr Rheumatol Rep. 2011 Feb;13(1):59-69.

Belimumab: a BLyS-specific inhibitor for systemic lupus erythematosus.
Ann Pharmacother. 2010 Dec;44(12):1955-61.

Updates on the treatment of lupus nephritis.
J Am Soc Nephrol. 2010 Dec;21(12):2028-35. Epub 2010 Nov 4. Review.

Drug Monitoring in Systemic Lupus Erythematosus: A Systematic Review.
Semin Arthritis Rheum. 2010 Oct 26. [Epub ahead of print]

Trials and tribulations in systemic lupus erythematosus.
Bull NYU Hosp Jt Dis. 2010;68(3):175-8. Review.

Alternative therapies: what role do they have in the management of lupus?
Lupus. 2010;19(12):1425-9. Review.

Accelerated atherosclerosis in systemic lupus erythematosus: role of proinflammatory cytokines and therapeutic approaches.
J Biomed Biotechnol. 2010;2010. pii: 607084. Epub 2010 Sep 26. Review.

Targeting B cells with biologics in systemic lupus erythematosus.
Expert Opin Biol Ther. 2010 Nov;10(11):1555-61. Epub 2010 Oct 4. Review.

Effects of community-deliverable exercise on pain and physical function in adults with arthritis and other rheumatic diseases: a meta-analysis.
Arthritis Care Res (Hoboken). 2011 Jan;63(1):79-93. doi: 10.1002/acr.20347.

B-cell targeted therapies in human autoimmune diseases: an updated perspective.
Immunol Rev. 2010 Sep;237(1):264-83. Review.

Clinical outcome measures for cutaneous lupus erythematosus.
Lupus. 2010 Aug;19(9):1137-43. Review.

Treatment of cutaneous lupus erythematosus.
Lupus. 2010 Aug;19(9):1125-36. Review.

Fatigue in systemic lupus erythematosus and rheumatoid arthritis.
PM R. 2010 May;2(5):384-92. Review.

Efficacy and adverse events of mycophenolate mofetil versus cyclophosphamide for induction therapy of lupus nephritis: systematic review and meta-analysis.
Medicine (Baltimore). 2010 Jul;89(4):227-35. Review.
Reporting of corticosteroid use in systemic disease trials: evidence from a systematic review of the potential impact on treatment effect.
Arthritis Care Res (Hoboken). 2010 Jul;62(7):1002-8. Review.

Danazol in the treatment of systemic lupus erythematosus: a qualitative systematic review.
Semin Arthritis Rheum. 2011 Feb;40(4):298-306. Epub 2010 Jun 11.

 

Or search the database yourself—it’s pretty easy. Enter “lupus trial” in the Search bar.

New Medical Therapies (NMT) Trial Results from Thomson CenterWatch
The database provides information about the results of recently completed and ongoing clinical trials. Select Systemic Lupus Erythematosus.

 

This information does not represent a Lupus Research Institute endorsement of any listed study. It is merely a notice that the study is available. If you are presently under the care of a physician for lupus or other conditions, you should not disrupt your current program without discussing it with your doctor(s). Do not contact the Lupus Research Institute for information on these studies. Only contact the listed numbers. The Lupus Research Institute does not have any jurisdiction over or further involvement with these studies, other than to make people aware that they are being conducted.